Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INP20 in peanut-allergic patients
NCT04163562Phase 2Recruiting
- Sponsor
- InnoUp Farma
- Start
- Mar 2020
- Primary completion
- May 2025
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy comparing INP20 with Placebo (2 arms). Primary endpoints: Incidence rate, severity, and relationship to treatment of adverse events and serious adverse events at Week 25 and Number of patients experiencing any dose limiting toxicity at Week 2. Started Mar 2020; status: recruiting.
02
Drugs
INP20
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT04163562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163562.